I am not a pumper, it's may be a desert walk on ONTY for awhile, but this I say. That ONTY is a sleeper that should be watched if you want to see something of real impact potentially FLY as more data comes in.
I am only here cuase that cnbc pump on sgen caught my interst but now I have questions about the small sample size of the nhl drug.
If they indeed include ALCL in BLA (not a given), I think the fda will use the advisory panel to slam the ALCL single arm - tiny sample results but in the end the fda will approve both indications. That may create a buying opp. after the panel meeting.
The ALCL indication adds about $50mm in rev./yr. JMworthlessO
I believe that the SGN-35 trial results in NHL are very compelling. Sample size is important but must be gauged in relation to the percentages at which the clinical response endpoints are met. In all comes down to the statistical analysis of the results......and the statistical findings in the NHL trial are very compelling that this drug "works".
In the SGN-35 trial in ALCL the patient sample size was even smaller, yet the results were equally compelling because the response rates were so high.
I have already commented on this in a prior note at the link below:
Of course, one cannot predict exactly how the FDA will handle any one particular drug review....but ( based on my review....for what little that might be worth ) the SGN-35 trial in NHL and ALCL present very favorable and quite convincing statistical evidence of efficacy in regard to their primary clinical endpoints.
Best of luck!
Disclosure Note: Ricardo is so biased, He has a huge long term position in the shares of SGEN
Neither of you know what you're talking about, especially basher nomoney, who already has acknowledged that he lost money shorting SGEN. The trial was designed in full association with the FDA. FDA approval is as close to a sure thing as you get in the biotech field.